Litcius/Paper detail

Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial)

Dominic Millenaar, Helmut Schumacher, Martina Brueckmann, John W. Eikelboom, Michael D. Ezekowitz, Jonathan Slawik, Sebastian Ewen, Christian Ukena, Lars Wallentin, Stuart J. Connolly, Salim Yusuf, Michael Böhm

2021The American Journal of Cardiology22 citationsDOI

Topics & Concepts

MedicinePolypharmacyAtrial fibrillationInternal medicineStroke (engine)Hazard ratioHeart failureDiabetes mellitusCardiologyBody mass indexWarfarinProportional hazards modelCoronary artery diseaseConfidence intervalMechanical engineeringEndocrinologyEngineeringAtrial Fibrillation Management and OutcomesMedication Adherence and ComplianceCardiac Arrhythmias and Treatments
Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial) | Litcius